Results 61 to 70 of about 4,929 (174)

Potential role of magnolol: A comprehensive review on its efficacy in managing neurological disorders

open access: yesBrain Disorders
Magnolol (MG) is a lignan compound isolated from Magnolia officinalis, renowned for its significant neuroprotective properties include the reduction of amyloid-beta toxicity and the inhibition of apoptotic pathways in neuronal cells.
Nasrin Sultana   +6 more
doaj   +1 more source

Real‐World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild‐Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using US Electronic Health Records

open access: yeseJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Light chain (AL) amyloidosis and transthyretin amyloid cardiomyopathy (ATTR‐CM) are the most common types of cardiac amyloidosis. Despite similar manifestations, prognosis and treatments are distinct, emphasizing the importance of accurate and timely diagnosis. This retrospective cohort study assessed real‐world diagnostic workups
Muhamed Baljevic   +7 more
wiley   +1 more source

Efficacy of omega‐3 fatty acids as a functional food: a multifaceted approach to health reinforcement

open access: yesJournal of the Science of Food and Agriculture, Volume 106, Issue 8, Page 4521-4549, June 2026.
Abstract Omega‐3 fatty acids (omega‐3s) are polyunsaturated fatty acids linked with numerous health benefits. Omega‐3s exhibit multifaceted activities through various mechanisms. Eicosapentaenoic acid (EPA) alleviates oxidative stress by lowering reactive oxygen species and improving oxidative stress in brain tissues and acts against neurodegenerative ...
Md Faruque Ahmad   +12 more
wiley   +1 more source

Beyond the Known and Established Neurodegenerative Effects: Roles of APOE Across a Wide Spectrum of Pathophysiological Condition

open access: yesMedComm, Volume 7, Issue 6, June 2026.
APOE is widely recognized for its role in neurodegeneration and cardiovascular disease, but its different genotypes also influence body composition, affecting obesity, bone density, and muscle mass, through their central role in lipid transport and metabolism.
Miriam Frosina   +5 more
wiley   +1 more source

Targeting Mitochondria in Aging‐Related Diseases: Therapeutic Potential and Obstacles

open access: yesMedComm, Volume 7, Issue 6, June 2026.
This article systematically summarized the specific mechanism of aging‐related diseases caused by mitochondrial dysfunction, and summarized the broad‐spectrum treatment methods and disease targeted treatment strategies for mitochondria. At the same time, it also pointed out the dilemma faced by mitochondrial targeted treatment.
Zijie Xiang   +12 more
wiley   +1 more source

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1118-1127, June 2026.
This exploratory analysis of data from the NEURO‐TTRansform trial evaluated sex‐specific responses in patients with ATTRv‐PN who had received eplontersen in NEURO‐TTRansform versus a historical placebo. Eplontersen can lead to substantial decreases in percentage serum TTR levels, arrest neuropathy impairment, and improve patient quality of life ...
Márcia Waddington Cruz   +11 more
wiley   +1 more source

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

open access: yesEuropean Journal of Haematology, Volume 116, Issue 6, Page 889-906, June 2026.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn   +3 more
wiley   +1 more source

Pharmacological Interventions for Hereditary Transthyretin‐Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta‐Analysis

open access: yesEuropean Journal of Neurology, Volume 33, Issue 6, June 2026.
We conducted a systematic review and network meta‐analysis on pharmacological therapies for ATTRv‐PN. Gene‐silencing therapies were more efficacious than stabilizers for neurological and quality‐of‐life outcomes; there were no differences in serious adverse events.
Gonçalo S Duarte   +6 more
wiley   +1 more source

Deep Phenotyping of F64L Mutation in a Multicentric Cohort of Patisiran‐Treated Hereditary Transthyretin Amyloidosis Patients (Patisiranitaly)

open access: yesEuropean Journal of Neurology, Volume 33, Issue 6, June 2026.
ABSTRACT Background The F64L variant is among the most frequent TTR mutations in Italy, typically associated with a predominantly neurologic phenotype and limited cardiac involvement. Methods Data from 181 ATTRv patients in the multicenter Patisiranitaly database treated with Patisiran since 2020 were analyzed. Neurologic impairment scores, Norfolk QoL‐
Marco Ceccanti   +53 more
wiley   +1 more source

The Long Haul: Microtubule Motors as the Essential Supply Line for Neuronal Longevity

open access: yesJournal of Neurochemistry, Volume 170, Issue 6, June 2026.
To survive a lifetime, neurons depend on a high‐fidelity logistics network powered by microtubule motors. We explore how a broad spectrum of genetic defects in this machinery drive a devastating spectrum of neurodevelopmental and neurodegenerative diseases, including Hereditary Spastic Paraplegia (HSP), Charcot–Marie‐Tooth Type 2 (CMT2), and ...
Emma D. Turner, Alison E. Twelvetrees
wiley   +1 more source

Home - About - Disclaimer - Privacy